Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by moe4on Feb 14, 2013 7:43pm
281 Views
Post# 20992068

just off the wire

just off the wire
ST. Andrew Goldfields earns $25.99-million in 2012
2013-02-14 18:34 SAS 0.51 SEDAR Audited Annual Financial Statements SEDAR Audited Annual Financial Statements
2013-02-14 18:34 SAS 0.51 SEDAR MD & A SEDAR MD & A

Mr. Jacques Perron reports

SAS REPORTS 2012 FOURTH QUARTER AND YEAR END RESULTS, BEATING CASH COST GUIDANCE, GENERATING $17.5 MILLION IN NET CASH FLOW AND PROVIDES 2013 GUIDANCE

St. Andrew Goldfields Ltd. earned net income attributable to shareholders for the fourth quarter of 2012, of $12.6-million, or three cents per share, as compared with net income of $12.9-million, or four cents on a per-share basis, for the fourth quarter of 2011. Operating cash flow in the quarter was $21.7-million or six cents per share, compared with operating cash flow for the same period last year of $14.0-million, or four cents per share.

For the fiscal year 2012, St. Andrews earned net income attributable to shareholders of $26.0-million or seven cents per share, as compared with net income of $17.2-million or five cents per share for fiscal year 2011. St. Andrews generated $54.1-million in cash flow from operations, or 15 cents on a per-share basis, compared with $23.4-million, or six cents per share, in fiscal year 2011

Bullboard Posts